Dec 22 (Reuters) – AstraZeneca said on Monday that a late‑stage trial testing Imfinzi in combination with ceralasertib failed to improve overall survival versus standard treatments in patients with previously treated advanced non‑small cell lung cancer.
The trial, called the LATIFY Phase III trial, evaluated 594 patients from more than 20 countries whose disease lacked targetable mutations and had progressed after prior immunotherapy and platinum-based chemotherapy.
“While we are disappointed by this result, we remain committed to pioneering new medicines to address the urgent need to improve outcomes for patients with lung cancer through our industry-leading portfolio,” said Susan Galbraith, executive vice-president of oncology haematology research and development at AstraZeneca.
Imfinzi is a human monoclonal antibody that blocks a tumour’s ability to evade the immune system and dampens it, while also boosting the body’s anti-cancer immune response, offering an alternative to chemotherapy.
The drugmaker’s ceralasertib-Imfinzi combination was generally well tolerated with no new safety concerns identified.
(Reporting by Yamini Kalia in Bengaluru; Editing by Rashmi Aich)
Comments